Apigenin Induces Apoptosis and Inhibits Migration in Human Cholangiocarcinoma Cells
Open Access
Abstract
Cholangiocarcinoma (CCA) is a rare and highly aggressive cancer of the biliary tract, associated with poor clinical outcomes due to late diagnosis, extensive metastasis, drug resistance, and limited treatment options. Apigenin, a natural flavonoid, has been found to exhibit anticancer properties in several types of human cancer cells. Therefore, apigenin may be relevant to developing chemotherapeutic agents for cancer treatment. In this study, we examined the effects of apigenin on cell viability, cell cycle distribution, apoptosis, and cell migration in human CCA cell lines (KKU-M055) under in vitro conditions. The results demonstrate that apigenin significantly suppressed specific CCA cell proliferation by inducing cell cycle arrest at the G2/M phase and promoting cell apoptosis in KKU-M055 cells while exhibiting low toxicity in immortalized MMNK1 cells. Apigenin enhanced apoptotic features, including nuclear fragmentation and the loss of mitochondrial membrane potential. Furthermore, apigenin induced the apoptosis of KKU-M055 cells in both extrinsic and intrinsic pathways by activating caspase-8, -9, and -3/7. Moreover, apigenin inhibited KKU-M055 migration. Our study suggests apigenin as a promising candidate for treating CCA, and these findings provide theoretical support for the further development and potential application of apigenin in clinical CCA therapy.Keywords
Funding Information
- Thailand Science Research and Innovation (TSRI) Fundamental Fund (2567)
- Thammasat University (2567)
This publication has 44 references indexed in Scilit:
- Improvement of survival outcomes of cholangiocarcinoma by ultrasonography surveillance: Multicenter retrospective cohortsHeliyon, 2024
- Discriminating Between Apoptosis, Necrosis, Necroptosis, and Ferroptosis by Microscopy and Flow CytometryCurrent Protocols, 2023
- A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening program compared to walk-in patientsHPB, 2020
- Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potentialEuropean Journal of Pharmaceutical Sciences, 2017
- Enhancing oral bioavailability using preparations of apigenin-loaded W/O/W emulsions: In vitro and in vivo evaluationsFood Chemistry, 2016
- Preparation, in-vitro release and antioxidant potential of formulation of apigenin with hydroxypropyl-β-cyclodextrin modified microemulsionJournal of Inclusion Phenomena and Macrocyclic Chemistry, 2016
- Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1expressionEnvironmental Toxicology, 2016
- Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cellsMolecular and Cellular Biochemistry, 2012
- Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathwaysBiochemical and Biophysical Research Communications, 2009
- Selective Growth-Inhibitory, Cell-Cycle Deregulatory and Apoptotic Response of Apigenin in Normal versus Human Prostate Carcinoma CellsBiochemical and Biophysical Research Communications, 2001